Cornerstone Research Group

What Cornerstone Research Group does

Cornerstone Research Group is a global health economic and market access research company founded in 2005 and headquartered in Burlington, Canada. The firm operates with 11-50 employees across North America, Europe, and Asia, serving pharmaceutical, biotechnology, and medical device companies with specialized HEOR (Health Economics and Outcomes Research), evidence synthesis, and market access services. Its team is composed predominantly of advanced-degree professionals (MSc, PhD, PharmD), with 50% cross-trained HEOR generalists and specialist experts in value communications, biostatistics, modeling, and evidence synthesis.

The firm's core offerings include systematic literature reviews, indirect treatment comparisons, health economic modeling, value communications, and HTA submission support, delivered as professional services engagements. Cornerstone Research Group has developed AI-enabled evidence synthesis capabilities including in-house large-language model tool development and AI support for JCA PICO prediction, and is noted for supporting approximately one-third of all Canadian HTA submissions while being one of only a few consultancies supporting multiple Joint Clinical Assessment dossier submissions under the new EU HTA regulation. Its deliverables are grounded in over 20 years of HTA experience and hundreds of published studies across therapeutic areas including oncology, rare disease, cardiometabolic, neurology, and immunology.

Cornerstone Research Group operates a consultative enterprise sales motion, engaging directly with pharmaceutical companies, medical device manufacturers, and biotechnology firms. Revenue derives primarily from professional services engagements (HEOR consulting, regulatory and compliance services) with supplementary subscription-style data and analytics products available through integration with the broader EVERSANA commercialization ecosystem. Customer segments span large enterprise pharmaceutical and medical device companies as primary clients and innovative biotechnology companies as a secondary segment, with global market expansion needs driving cross-region engagements across North America, Europe, and Asia.

Name

Cornerstone Research Group

Legal name

Data source pertains to EVERSANA, not Cornerstone Research Group. No legal name available for Cornerstone Research Group in provided source data.

Website

https://cornerstone-research.com

Company type

Private

Founded year

2005

Headcount range

11–50 employees

Short description

Cornerstone Research Group is a global health economic and market access research company that provides AI-enabled HEOR, evidence synthesis, and HTA submission services to pharmaceutical, biotechnology, and medical device companies across North America, Europe, and Asia.

Ownership category

akta.pro rank

Headquarters

HQ city

Burlington

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Revenue model

1. HEOR and Market Access Consulting Services: Strategic evidence generation and consulting services including systematic literature reviews, indirect treatment comparisons, health economic modeling, value communications, and HTA submission support. Delivered as professional services engagements.
2. Regulatory and Compliance Services: Medical affairs, pharmacovigilance, quality assurance, and regulatory medical affairs services supporting product lifecycle from development through post-launch.
3. Data and Analytics Products: Commercial analytics, integrated patient analytics, real-world evidence platforms, and market access data products including NAVLIN pricing and access data solutions.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Cornerstone Research Group is a global health economic and market access research company that delivers research services to life sciences clients. Founded in 2005 and based in Burlington, Canada, it operates as a small, privately held firm (11-50 employees) serving the pharmaceutical, biotechnology, and medical device sectors with health economics and market access research.

Product overview

EVERSANA is an integrated life sciences commercialization platform that offers a comprehensive suite of services and products spanning market access, HEOR, data & analytics, AI-enabled marketing, and compliance operations. The portfolio includes NAVLIN data products (Price & Access Data, Research & Insights, Software, Revenue Management), Commercial Intelligence 360 analytics platform, AI Agency Platform in partnership with Google, Donor Eligibility System, and Omnichannel/Machine & Legal Reviews AI products. These offerings work together as an integrated ecosystem connecting data, analytics, evidence generation, and activation across the product lifecycle.

Differentiator

Problem solved

Functional benefit

Products and services

• Health Economics and Market Access Research Global health economic and market access research services for life sciences clients, including pharmaceutical, biotechnology, and medical device companies.

Quantifiable outcome

• Supports approximately one-third of all Canadian HTA submissions
• +1 more outcomes

Named customers3 records

Segments4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

One partnership is on record.

• GooglecoreTechnology or IntegrationProven AI platform partnership with Google for AI-enabled marketing solutions where clients control data, outputs, and commercial roadmap. Includes AI Agency Platform collaboration.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• IQVIA: Largest global life sciences services platform with a substantial HEOR, real-world evidence, and market access practice. Competes for the same enterprise pharma engagements as CRG but at much greater scale and breadth.
• Syneos Health: Biopharmaceutical services organization covering clinical development through commercialization, including market access and HEOR capabilities. A broader competitor that can absorb smaller niche engagements.
• ICON plc: Global CRO and clinical research services firm with post-2023 expansion into HEOR and market access consulting. Represents a scaled, integrated competitor for sponsors seeking end-to-end evidence and access support.
• Parexel International: Global CRO with a market access and HEOR practice serving pharma and biotech sponsors. Competes with CRG for evidence generation and HTA submission mandates, especially in oncology and rare disease.

Direct peers

• RTI Health Solutions: Not-for-profit-affiliated HEOR and market access consultancy offering health economics, real-world evidence, and HTA submission support. Closely comparable in service scope and therapeutic-area expertise.
• EVERSANA: Integrated life sciences commercialization platform with a sizable HEOR, market access, and evidence generation practice. Most comparable in service mix to CRG and the dominant counterparty in the structured data attached to this profile.
• Cytel: Biostatistics and HEOR consultancy serving pharmaceutical and biotech sponsors with evidence synthesis, indirect treatment comparisons, and health economic modeling - directly overlapping CRG's core offerings.
• Charles River Associates (CRA): Consulting firm with a Life Sciences practice providing HEOR, pricing, and market access advisory services. Comparable to CRG in the consulting-led HEOR segment, particularly for global pharma sponsors.
• PRECISIONheor (Precision Medicine Group): Specialist HEOR and market access consultancy within Precision Medicine Group. Competes head-to-head with CRG on HTA submissions, value communications, and evidence generation for pharma and biotech.
• Xcenda (Cencora): HEOR, market access, and reimbursement consultancy owned by Cencora (formerly AmerisourceBergen). A long-standing competitor to niche HEOR firms like CRG, particularly in payer evidence and access strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cornerstone Research Group